$STNE

StoneCo Q2 Earnings Call Highlights

StoneCo (NASDAQ: STNE) reported Q2 results on an earnings call. Adjusted net income fell slightly YoY, but adjusted EPS rose 9% on a lower share count from repurchases. For 1H, it posted BRL 3.1B adjusted gross profit and BRL 4.58 adjusted basic EPS, and kept 2026 guidance. Management cited higher-for-longer Selic rates, retention efforts, Pix growth, and rising credit costs.

Original reporting
Published Aug 14, 2026, 3:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
StoneCo Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$STNENeutralMed
01

Why it matters

Traders should focus on the updated macro assumption for Selic, the provision and cost-of-risk drivers (portfolio growth, loan vintage aging, dedicated desk defaults), and the stated path for cost of risk into year-end.

02

Market read

The piece is a management update with specific quantitative guidance, macro sensitivity, credit portfolio growth, provision/cost-of-risk metrics, and a year-end cost-of-risk target, all of which can move estimates and positioning.

03

What to watch

The article notes potential additional provisions tied to litigation-weighted scenarios for distressed card issuers; that accounting uncertainty could dominate near-term earnings variability more than retention metrics.

Relevance 7/10Novelty 6/10Timing: ahead of next earnings and into 2H as cost-of-risk and retention trends develop

Background

StoneCo’s Q2 call frames a turnaround with guidance maintained, while emphasizing macro-driven credit pressure and operational retention improvements.

Company-level read

Ticker impact

$STNENeutralMedium confidence
Context

StoneCo maintained 2026 guidance while flagging Selic rate risk, rising credit portfolio, and cost-of-risk trajectory toward high teens by year-end.

Expected impact

Near-term volatility risk, with downside skew if cost of risk or provisions re-accelerate versus management’s mid-to-high teens path.

Evidence & confidence

The article provides concrete management assumptions (Selic ~14% vs 12.5%), portfolio growth and provision/cost-of-risk metrics, plus an explicit medium-term cost-of-risk range and year-end target, which can drive estimate revisions even without a guidance cut.

Market effects

Brazil payments and merchant-fintech peers may face read-across on credit underwriting, Pix mix dynamics, and government-guaranteed lending sensitivity to Selic.

Highlights how Brazilian rates and credit conditions are feeding into fintech funding costs and provisions, potentially influencing local investor risk appetite.

Limited direct global spillover, but it can affect international fintech sentiment toward LATAM credit-linked payment platforms.

Counterpoint

If government-backed lending continues to expand and the automated lending desk improvements persist, cost of risk could stabilize below the high-teens year-end expectation.

Key entities

  • StoneCo Ltd.

    Brazilian payments and merchant financial services provider; subject of the earnings call highlights.

  • Selic benchmark rate

    Brazil’s policy rate assumption that management says materially impacts pretax results and credit economics.

  • FGI Pix program

    Government guarantee scheme that reduces loss given default and upfront provisions for eligible loans.

  • Pagar.me

    Digital-commerce platform integrated into Stone to unify merchant accounts and views across online and in-person sales.

Related articles

$STNEMed

Why is StoneCo stock sliding today?

StoneCo Ltd shares fell 2% in after-hours after its Q2 2026 results beat adjusted EPS but missed revenue. Adjusted EPS was R$2.40, in line with consensus, while revenue was R$3.59B vs R$3.67B expected. Adjusted net income fell 2.6% YoY to R$582.7M. Investors cited a 107.5% YoY jump in its credit portfolio and concerns tied to Brazil’s high rates.

$SLFMed

Street Calls of the Week By Investing.com

Investing.com’s weekly Wall Street recap covers downgrades: Evercore cut Sun Life Financial (SLF) to Inline, citing valuation upside tapped out and operational friction, with a $111 target. Mizuho downgraded Circle Internet (CRCL) to Underperform, $50 target, on stablecoin margin pressure. BofA lowered StoneCo (STNE) to Neutral, $13, on Brazil rate-driven credit risk. BTIG downgraded Etsy (ETSY) to Neutral. Goldman downgraded Regions Financial (RF) to Neutral, $36, citing weaker buybacks and gui

$SPRYMed

ARS Pharmaceuticals Q2 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) said it expanded its field sales force and will target high-value prescribers, noting neffy has about 8% market share in the field-targeted universe versus ~1% in non-targeted. Commercial coverage is 90%. Q2 operating expenses were $95.1M. ARS expects cash-flow breakeven by end-2027 and Phase IIb CSU interim data in Q1 2027.

$SSTIMed

SoundThinking Q2 Earnings Call Highlights

SoundThinking (NASDAQ:SSTI) said Q2 delays in professional-services work and slower SafePointe deployments reduced its 2026 revenue outlook by about $2 million and shifted some work into 2027. It also removed a nearly $1.5 million Puerto Rico ShotSpotter recapture from 2026 guidance and cut full-year adjusted EBITDA margin to 8% to 9%. ShotSpotter bookings and go-lives lagged, while renewals totaled over $23 million and a Texas TAG CrimeTracer deal adds about $2.5 million in annual recurring rev

$MRXMedAI 8/10

Marex reports $318m profit for first half

Marex reported record adjusted profit before tax of $318m for the first half, up 79% year on year, and record Q2 adjusted profit before tax of $165.9m. Q2 after-tax profit was $155.3m, including a $35.1m gain from selling Winterflood’s custody business. Marex cited redomiciliation to Bermuda and revenue growth across segments.

$MDLNMed

Medline (MDLN) Q2 2026 Earnings Call Transcript

Medline (MDLN) Q2 2026 call said adjusted EBITDA rose 13% YoY to $1.1B, with higher costs partly offset by a $243M IEEPA tariff refund benefit. Q2 net sales grew 12% to $7.7B. Company raised fiscal 2026 organic sales outlook, but moderated adjusted EBITDA outlook citing Middle East conflict, Tracy warehouse fire, investments, quality remediation, and retail softness.